Episode
E24: NMDA Receptor Antagonists: Ketamine, Esketamine (Spravato), and Dextromethorphan+Bupropion (Auvelity)
- Published
- Jan 30, 2025
- Duration seconds
- 3674
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/this-is-your-brain-on-drugs-psychiatry-podcast-7023342/episodes/e24-nmda-receptor-antagonists-ketamine-esketamine-spravato-and-dextromethorphan-bupropion-auvelity/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/this-is-your-brain-on-drugs-psychiatry-podcast-7023342/e24-nmda-receptor-antagonists-ketamine-esketamine-spravato-and-dextromethorphan-bupropion-auvelity.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Today we have an interesting episode. We are covering the first of a very new class of antidepressants, the NMDA receptor antagonists. These are the first antidepressants approved for use for depression which do not interact with the monoamine system, and many more may be coming out in the future. We will talk about ketamine, its sister, esketamine, and the only oral form, a combination of the cough suppressant dextromethorphan and bupropion. Find out how this new class of antidepressant works for depression and what my opinion is of these new medications!